Yunli Wu

Dr. Yunli Wu

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2017 in Scientific Reports
Verified
Journal Article
Open access
ZSZhi-Jun Su
Zhi-Jun Su
JCJia-Shou Cao
Jia-Shou Cao
YWYan-Fang Wu
Yan-Fang Wu
WCWan-Nan Chen
Wan-Nan Chen
XLXinjian Lin
Xinjian Lin
XLXu Lin
Xu Lin
Hepatitis B virus X protein (HBx) plays important roles in viral replication and the development of hepatocellular carcinoma. HBx is a rapid turnover protein and ubiquitin-proteasome pathway has been suggested to influence HBx stability as treatment with proteasome inhibitors increases the levels of HBx protein and causes accumulation of the polyubiquitinated forms of HBx. Deubiquitinases (DUBs) are known to act by removing ubiquitin moieties from proteins and thereby reverse their stability and/or activity. However, no information is available regarding the involvement of DUBs in regulation of ubiquitylation-dependent proteasomal degradation of HBx protein. This study identified the deubiquitylating enzyme USP15 as a critical regulator of HBx protein level. USP15 was found to directly interact with HBx via binding to the HBx region between amino acid residues 51 and 80. USP15 increased HBx protein levels in a dose-dependent manner and siRNA-mediated knockdown of endogenous USP15 reduced HBx protein levels. Increased HBx stability and steady-state level by USP15 were attributable to reduced HBx ubiquitination and proteasomal degradation. Importantly, the transcriptional transactivation function of HBx is enhanced by overexpression of USP15. These results suggest that USP15 plays an essential role in stabilizing HBx and subsequently affects the biological function of HBx.

10 August 2022 in Infectious Medicine
Verified
Journal Article
Open access
DWDong Wang
Dong Wang
XCXiao-Ling Cai
Xiao-Ling Cai
XLXu Lin
Xu Lin
JZJing Zheng
Jing Zheng
YWYunli Wu
Yunli Wu
XPxiane peng
xiane peng
The incidence of liver injury caused by anti-tuberculous (TB) drugs is very high. However, owing to a lack of sufficient evidence, preventive use of hepatoprotective drugs is not yet recommended. Therefore, we aimed to assess the protective effect of hepatoprotective drugs for anti-TB drug-induced liver injury. We conducted a literature search in China Biology Medicine disc, China National Knowledge Infrastructure, WanFang, Chinese Scientific and Technological Journal, PubMed, Cochrane Library, Web of Science, and Embase. We performed meta-analysis using R 4.0 and Review Manager 5.3 software. A total of 18 studies involving 3589 patients from 2 groups were included. Use of hepatoprotective drugs contributed to a lower incidence of liver injury as compared with conventional anti-TB treatment alone (relative risk [RR] = 0.39, 95% confidence interval [CI]: 0.28–0.53, p < 0.001). In subgroup analysis, significant protective effects were noted for mild liver injury (RR = 0.30, 95% CI 0.15–0.58), moderate (or severe) liver injury (RR = 0.35, 95% CI 0.19–0.65), and liver injury within 2–4 weeks (RR = 0.37, 95% CI 0.19–0.71). We also found a statistically significant difference in the incidence of drug withdrawal (RR = 0.58, 95% CI 0.34–0.97, p = 0.040). Our results demonstrate that hepatoprotective drugs are effective in preventing liver injury in patients receiving anti-TB treatment, to some extent.

26 December 2024 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Open access
HFHua Fang
Hua Fang
HCHuajing Chang
Huajing Chang
DCDanjing Chen
Danjing Chen
WQWenxin Qiu
Wenxin Qiu
JFJiangwang Fang
Jiangwang Fang
XPxiane peng
xiane peng
Previous studies have demonstrated perfluoroalkyl and polyfluoroalkyl substances (PFAS) impact renal function, with albumin playing dominant role in their transport and accumulation. However, the mediating role of albumin in PFAS-induced renal impairment and the identification of sensitive populations remain uninvestigated. This study included 9328 individuals from NHANES 1999-2018 with data on serum PFAS, creatinine, albumin, and covariates. The estimated glomerular filtration rate (eGFR) was calculated using standardized creatinine. Associations between perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), perfluorohexane sulfonate (PFHxS), and perfluorononanoic acid (PFNA) with eGFR and the risk of decreased renal function (eGFR < 90 vs. eGFR ≥ 90) using linear and logistic regression, weighted quantile sum (WQS) regression, Bayesian kernel machine regression (BKMR), and restricted cubic spline (RCS) analyses. Subgroup analyses identified sensitive populations. Mediation analysis was performed to examine the mediating role of albumin. Comparative toxicology databases identified relevant genes for mechanistic exploration. Ln-transformed PFOA (β = -1.91, 95 % CI: -2.82 to -1), PFOS (β = -1.48, 95 % CI: -2.19 to -0.78) and PFHxS (β = -0.94, 95 % CI: -1.65 to -0.23) were negatively correlated with eGFR. PFOA (aOR = 1.21, 95 % CI: 1.1-1.32), PFOS (aOR = 1.2, 95 % CI: 1.12-1.29), and PFHxS (aOR = 1.13, 95 % CI: 1.05-1.21) were positively correlated with the risk of decreased renal function. Subgroup analyses indicated that individuals ≤ 45 years, females and other races were more sensitive. Albumin mediated 18.2 %, 16.4 %, 29.8 %, and 18.7 % of the negative effects of PFOA, PFOS, PFHxS, and PFNA on eGFR, respectively. Functional enrichment analysis suggested PFAS impair renal function by affecting lipid metabolism and increasing oxidative stress. PFAS exposure is negatively associated with eGFR and positively associated with the risk of decreased renal function, with albumin playing a partial mediating role.

19 November 2024 in Journal of Virology
Verified
Journal Article
Closed access
YWYunli Wu
Yunli Wu
LRLan Ren
Lan Ren
CMChenglei Mao
Chenglei Mao
ZSZhiqing Shen
Zhiqing Shen
WZWenyu Zhu
Wenyu Zhu
XLXu Lin
Xu Lin
Persistent infection with hepatitis B virus (HBV) often leads to disruptions in lipid metabolism. Apolipoprotein AII (apoAII) plays a crucial role in lipid metabolism and is implicated in various metabolic disorders. However, whether HBV could regulate apoAII and contribute to HBV-related dyslipidemia and the underlying mechanism remain unclear. This study revealed significant reductions in apoAII expression in HBV-expressing cell lines, the serum, and liver tissues of HBV-transgenic mice. The impact of HBV on apoAII is related to small hepatitis B virus surface antigen (SHBs). Overexpression of SHBs decreased apoAII levels in SHBs-expressing hepatoma cells, transgenic mice, and the serum of HBV-infected patients, whereas suppression of SHBs increased apoAII expression. Mechanistic investigations demonstrated that SHBs repressed the apoAII promoter activity through a HNF4α- and C/EBPγ-dependent manner; SHBs simultaneously upregulated C/EBPγ and downregulated HNF4α by inhibiting the PI3K/AKT signaling pathway through activating endoplasmic reticulum (ER) stress. Serum lipid profile assessments revealed notable decreases in high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), and triglycerides (TG) in SHBs-transgenic mice compared to control mice. However, concurrent overexpression of apoAII in these mice effectively counteracted these reductions in lipid levels. In HBV patients, SHBs levels were negatively correlated with serum levels of HDL-C, LDL-C, TC, and TG, whereas apoAII levels positively correlated with lipid content. This study underscores that SHBs contributes to dyslipidemia by suppressing the PI3K/AKT pathway via inducing ER stress, leading to altered expression of HNF4α and C/EBPγ, and subsequently reducing apoAII expression. IMPORTANCE: The significance of this study lies in its comprehensive examination of how the hepatitis B virus (HBV), specifically through its small hepatitis B virus surface antigen (SHBs), impacts lipid metabolism—a key aspect often disrupted by chronic HBV infection. By elucidating the role of SHBs in regulating apolipoprotein AII (apoAII), a critical player in lipid processes and associated metabolic disorders, this research provides insights into the molecular pathways contributing to HBV-related dyslipidemia. Discovering that SHBs downregulates apoAII through mechanisms involving the repression of the apoAII promoter via HNF4α and C/EBPγ, and the modulation of the PI3K/AKT signaling pathway via endoplasmic reticulum (ER) stress, adds critical knowledge to HBV pathogenesis. The research also shows an inverse correlation between SHBs expression and key lipid markers in HBV-infected individuals, suggesting that apoAII overexpression could counteract the lipid-altering effects of SHBs, offering new avenues for understanding and managing the metabolic implications of HBV infection.

1 September 2024 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
SRShutong Ren
Shutong Ren
SCSiyu Chen
Siyu Chen
JHJingru Huang
Jingru Huang
RYRong Yu
Rong Yu
YWYunli Wu
Yunli Wu
XPxiane peng
xiane peng
Objective: This study aimed to explore the association between serum uric acid (sUA) levels and metabolic-associated fatty liver disease (MAFLD) in Southeast China. Methods: We performed a cross-sectional study of 2605 subjects who underwent physical examination between 2015 and 2017 in Southeast China. To explore the association between sUA levels and the risk of MAFLD, we employed logistic regression, restricted cubic spline (RCS), subgroups and multiplicative interaction analysis. Results: Logistic regression analysis showed a positive association between sUA and MAFLD [aOR total population (95% CI)= 1.90 (1.49 ~ 2.42)], [aOR male (95% CI)= 2.01 (1.54 ~ 2.62)], [aOR female (95% CI)= 1.15 (0.62 ~ 2.11)], respectively. The RCS plot presented a significant nonlinear dose–response relationship between sUA levels and MAFLD risk, and the risk of MAFLD increased significantly when sUA> 5.56 mg/dL (Pnonlinear< 0.001). Subgroups analysis revealed that the positive association between sUA and MAFLD was consistent across strata of gender, age, BMI, drinking status, smoking status and tea drinking status. Significant associations between sUA and MAFLD were not only found in males but also existed in subjects whose age ≤ 60, BMI ≥ 24 kg/m2, drinkers, smokers and tea-drinkers. Adjusted ORs were estimated to be 2.01, 1.95, 2.11, 2.29, 2.64 and 2.20, respectively. Multiplicative interactions were not observed between gender, age, drinking status, smoking status, tea drinking status and sUA (all P interaction> 0.05). Conclusion: According to our study, sUA was positively associated with the risk of MAFLD. Additionally, the risk of MAFLD increased significantly when sUA levels exceeded 5.56 mg/dL. Our study may help clarify whether sUA plays a diagnostic role in MAFLD.

8 April 2026 in European Journal of Pharmacology
Verified
Journal Article
Closed access
LRLan Ren
Lan Ren
DWDong Wang
Dong Wang
YHYun He
Yun He
XWXiaolei Wu
Xiaolei Wu
WZWenyu Zhu
Wenyu Zhu
YWYunli Wu
Yunli Wu